Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial - Eli Lilly
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.